JPWO2022032137A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022032137A5
JPWO2022032137A5 JP2023507911A JP2023507911A JPWO2022032137A5 JP WO2022032137 A5 JPWO2022032137 A5 JP WO2022032137A5 JP 2023507911 A JP2023507911 A JP 2023507911A JP 2023507911 A JP2023507911 A JP 2023507911A JP WO2022032137 A5 JPWO2022032137 A5 JP WO2022032137A5
Authority
JP
Japan
Prior art keywords
combination
pharmaceutical
statin
dose
angptl3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538522A (ja
JP2023538522A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045008 external-priority patent/WO2022032137A1/en
Publication of JP2023538522A publication Critical patent/JP2023538522A/ja
Publication of JPWO2022032137A5 publication Critical patent/JPWO2022032137A5/ja
Publication of JP2023538522A5 publication Critical patent/JP2023538522A5/ja
Abandoned legal-status Critical Current

Links

JP2023507911A 2020-08-07 2021-08-06 Angptl3阻害剤を伴う難治性高コレステロール血症を処置するための方法 Abandoned JP2023538522A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063062990P 2020-08-07 2020-08-07
US63/062,990 2020-08-07
US202163135946P 2021-01-11 2021-01-11
US63/135,946 2021-01-11
PCT/US2021/045008 WO2022032137A1 (en) 2020-08-07 2021-08-06 Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor

Publications (3)

Publication Number Publication Date
JP2023538522A JP2023538522A (ja) 2023-09-08
JPWO2022032137A5 true JPWO2022032137A5 (https=) 2024-08-09
JP2023538522A5 JP2023538522A5 (https=) 2024-08-09

Family

ID=77543654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507911A Abandoned JP2023538522A (ja) 2020-08-07 2021-08-06 Angptl3阻害剤を伴う難治性高コレステロール血症を処置するための方法

Country Status (11)

Country Link
US (2) US20220072127A1 (https=)
EP (1) EP4192446A1 (https=)
JP (1) JP2023538522A (https=)
KR (1) KR20230050379A (https=)
CN (1) CN116096365A (https=)
AU (1) AU2021320417A1 (https=)
BR (1) BR112023002085A2 (https=)
CA (1) CA3188213A1 (https=)
IL (1) IL300429A (https=)
MX (1) MX2023001481A (https=)
WO (1) WO2022032137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Angptl3阻害剤と組み合わせてpcsk9阻害剤を投与することにより高脂血症を有する患者を処置するための方法
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
KR20240167914A (ko) * 2022-04-04 2024-11-28 이노자임 파마, 인코포레이티드 Enpp1 결핍증 및 abcc6 결핍증의 치료
WO2025185644A1 (zh) * 2024-03-05 2025-09-12 江苏恒瑞医药股份有限公司 抗angptl3抗体治疗高血脂症的用途及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
RU2723018C2 (ru) * 2014-07-16 2020-06-08 Санофи Байотекнолоджи Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
JP7541810B2 (ja) * 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Angptl3阻害剤と組み合わせてpcsk9阻害剤を投与することにより高脂血症を有する患者を処置するための方法
KR20180132843A (ko) * 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
IL293308B2 (en) * 2016-04-28 2024-12-01 Regeneron Pharma Methods for treating patients with familial hypercholesterolemia

Similar Documents

Publication Publication Date Title
JP2022177142A5 (https=)
JP2019514907A5 (https=)
JP2022133396A5 (https=)
US20240417455A1 (en) Treatment for rheumatoid arthritis
HRP20250797T1 (hr) Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2021515772A5 (https=)
RU2013139727A (ru) Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
JP2014516953A5 (https=)
JP2016538248A5 (https=)
JP2013023499A5 (https=)
HRP20200545T1 (hr) Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom
JP2015530867A5 (https=)
JP2017528427A5 (https=)
JP2021523188A5 (https=)
JP2022000443A5 (https=)
JP2019512472A5 (https=)
JP2017506626A5 (https=)
JP2016538277A5 (https=)
RU2015101113A (ru) Антитела против pcsk9, составы, дозы и способы применения
JP2017522316A5 (https=)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
IL310115A (en) Treatment of his hyporesponders
JPWO2022032137A5 (https=)
CN1642574A (zh) 用于肾小球疾病的治疗剂